Where the money came from
Botulinum toxin products, Medytox's main line, brought in 35.5 billion won in the quarter. The domestic business held steady, and the source names Coretox as the South Korean product that kept sales level. Overseas revenue for the toxin lines rose 17% year on year. The company credits a dual-brand approach built on Meditoxin and Newlux. Newlux is a next-generation toxin formulation developed by affiliate Newmeco.
Nubijou is the newer piece. It is a fat-reduction injectable that contains cholic acid. The source says South Korea's Ministry of Food and Drug Safety approved it as the country's 40th domestically developed new drug. A Medytox official said the product "sped up its spread into the domestic market and hit this year's sales target early. The document gives no Nubijou revenue figure. I cannot tell you how much of the 35.5 billion won toxin total it accounts for, or whether it sits in that line at all.
The filler problem
Hyaluronic acid fillers were the weak spot. The company says that segment fell temporarily because it realigned its global sales channels. Its fix is a direct-export model that drops intermediate distributors.
For owners who buy Neuramis product, the timing matters. Medytox expects overseas filler revenue to recover from the fourth quarter, when local supply begins in earnest for two Neuramis fillers, Deep Lidocaine and Volume Lidocaine. Both received approval from China's National Medical Products Administration (NMPA). That is a Chinese regulator. It is not an FDA action. Nothing in the document speaks to U.S. status. In South Korea, the company plans to go after skin booster demand with Neuramis Skin Enhancer.
What it means for practices
Analysis: a toxin maker that grows abroad while cutting its own selling costs is telling you its distribution cost is the lever, not its price. If you carry Medytox product, expect the company to push direct. A direct-export model can mean a cleaner supply chain for buyers. It can also mean fewer local intermediaries to call when a lot is delayed. Ask your distributor which side of that change you sit on before the fourth quarter.
The consumer-side moves matter less to a clinic buyer but show where the company is putting its effort. Neuraderm is entering Olive Young and Musinsa Beauty and preparing a new Daily Essential line. Lactiplan, a probiotic the company describes as aimed at reducing body fat, is moving from pharmacies to online platforms.
What owners can do
If you stock or plan to stock Medytox toxins, ask for the current NMPA and MFDS status of any product you are considering, in writing, from the supplier. Do not rely on a Korean approval for a U.S. or other market. If you hold Neuramis filler, watch your fourth-quarter supply. The company has tied its filler recovery to that quarter, so a delay now is a signal worth raising early. If you buy Nubijou or any cholic-acid injectable, confirm the approval scope in the product literature. The source gives only a Korean approval, with no indication details beyond the fat-reduction label.
What we don't know
The document does not break out Nubijou revenue, does not say how large the overseas toxin market was in the quarter, and does not name a dollar figure for the filler decline. It gives no FDA status for any Medytox product. The company's "record revenue this year" target is a stated goal, and the quarter's 2.8% revenue drop makes it a harder bar to clear. The source is an AI-translated Korean report, so the quotes are secondhand and may not match the original wording.
Business information, not medical or legal advice. Verify regulatory status at FDA.gov.